Announcement

Collapse
No announcement yet.

STEMCELLS, Switzerland

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • STEMCELLS, Switzerland

    Is there an update on the clinical trials in Switzerland being conducted by STEMCELLS?

  • #2
    Just to be clear, the SCINurse above (with no profile) is not one of the moderators here. We are SCI-Nurse.

    (KLD)
    The SCI-Nurses are advanced practice nurses specializing in SCI/D care. They are available to answer questions, provide education, and make suggestions which you should always discuss with your physician/primary health care provider before implementing. Medical diagnosis is not provided, nor do the SCI-Nurses provide nursing or medical care through their responses on the CareCure forums.

    Comment


    • #3
      I didn't notice until you pointed that out ... they should have a name change to avoid confusion!
      Roses are red. Tacos are enjoyable. Don't blame immigrants, because you're unemployable.

      T-11 Flaccid Paraplegic due to TM July 1985 @ age 12

      Comment


      • #4
        Originally posted by SCINurse View Post
        Is there an update on the clinical trials in Switzerland being conducted by STEMCELLS?
        Stem cell inc are using Bulgrast university hospital as their research centre. what we call clinical trials they prefer to use the word clinical study as that what it really is a study. They have just finished 3 ASIA A participants in which 20microl ltrs of neural fetal cells where injected above, below and into injury. 3 participants from each ASIA scale 12 in all will be done over a period of 4 years.
        The study is mainly safety based and not efficacy based.

        After this 4 year period that is if safety is proven. the study may increase the cell dose to 50microlts use, scaffolds to promote growth and also use a variant of nogo inhibitors. Here is an e mail address of a study doctor involved in the trail if you wish to participate or require further info Axel.Marzeion@balgrist.ch

        Comment


        • #5
          Originally posted by peterf View Post
          Stem cell inc are using Bulgrast university hospital as their research centre. what we call clinical trials they prefer to use the word clinical study as that what it really is a study. They have just finished 3 ASIA A participants in which 20microl ltrs of neural fetal cells where injected above, below and into injury. 3 participants from each ASIA scale 12 in all will be done over a period of 4 years.
          The study is mainly safety based and not efficacy based.

          After this 4 year period that is if safety is proven. the study may increase the cell dose to 50microlts use, scaffolds to promote growth and also use a variant of nogo inhibitors. Here is an e mail address of a study doctor involved in the trail if you wish to participate or require further info Axel.Marzeion@balgrist.ch
          i was not aware that the 4 years were all for saftey. why so long? wise youngs trial saftey stage isnt but a year, correct?

          Comment


          • #6
            4 years is a long time. Maybe that is how long they feel it will take in order to find and establish safety. There could be concern for long-term cell behavior?

            Comment


            • #7
              Aileen explains the trial design here.http://vimeo.com/39767940
              http://spinalcordresearchandadvocacy.wordpress.com/

              Comment


              • #8
                I had personally applied as a participant and was accepted for a screening test in Switzerland which did not deliver. what i have told you is what Dr Armin Curt
                (Hospital director) had informed me about the study and the protocol agreement signed between candidate and stem cell inc. As of this 4 year study Dr Curt gave an assessment percentage that the study would prove to be safe at 90% but as to candidates gaining any recovery this he put at 4%. Once the safety aspect has been proven i do believe that stem cell inc will try many other alternative routes using the same cells to prove efficacy however as of now candidate safety is supreme.
                Last edited by peterf; 05-03-2012, 06:28 AM.

                Comment


                • #9
                  chaz abd Peter, last month Stem Cell INc put put a report from their phase one trial for disease that young people who do not produce myelin. They said that the 4 pateints showed evidence of producing myelin through injection of neurol cells in the brain of the pateints. this has never been accomplished before and the patents of this disease usually pass away before 10 years of AGE. Perhaps we might get some evidence of efficay of this trial also. 4% is very low and is somewhat disappointing prediction.

                  Comment


                  • #10
                    Originally posted by peterf View Post
                    Stem cell inc are using Bulgrast university hospital as their research centre. what we call clinical trials they prefer to use the word clinical study as that what it really is a study. They have just finished 3 ASIA A participants in which 20microl ltrs of neural fetal cells where injected above, below and into injury. 3 participants from each ASIA scale 12 in all will be done over a period of 4 years.
                    The study is mainly safety based and not efficacy based.

                    After this 4 year period (that is if safety is proven). The study may increase the cell dose to 50microlts use, scaffolds to promote growth and also use a variant of nogo inhibitors.
                    I believe the moral of the story is that stem cells just can't be poked into the spinal cord and miracles happen. Safety must be proven for the cells and then other factors need to used in combination for good outcomes. This all takes time to get through the necessary steps.
                    http://spinalcordresearchandadvocacy.wordpress.com/

                    Comment


                    • #11
                      Are nogo inhibitors proved on chronics? Do scaffolds have something with scar tissue or nogo inhibitors can do bit for scar?

                      Comment


                      • #12
                        https://www.carecure.net/forum/showp...6&postcount=62

                        Journal of Neurotrauma
                        ..
                        Delayed Anti-Nogo-A Antibody Application after Spinal Cord Injury Shows Progressive Loss of Responsiveness

                        Roman R. Gonzenbach,1 Bjoern Zoerner,2 Lisa Schnell,2 Oliver Weinmann,2 Anis K. Mir,3 and Martin E. Schwab4
                        1UniversitätsSpital Zürich, Neurologische Klinik, Zürich, Switzerland.
                        2Brain Research Institute, University of Zurich, Switzerland, Zürich, Switzerland.
                        3Novartis Pharma, Basel, Switzerland.
                        4University and ETH Zurich, University of Zurich, Switzerland, Zürich, Switzerland.

                        ABSTRACT


                        Blocking the function of the myelin protein Nogo-A or its signaling pathway is a promising method to overcome an important neurite growth inhibitory factor of the adult central nervous system (CNS), and to enhance axonal regeneration and plasticity after brain or spinal cord injuries. Several studies have shown increased axonal regeneration and enhanced compensatory sprouting, along with substantially improved functional recovery after treatment with anti-Nogo-A antibodies, Nogo-receptor antagonists, or inhibition of the downstream mediator RhoA/ROCK in adult rodents. Proof-of-concept studies in spinal cord-injured macaque monkeys with anti-Nogo-A antibodies have replicated these findings; recently, clinical trials in spinal cord-injured patients have begun. However, the optimal time window for successful Nogo-A function blocking treatments has not yet been determined. We studied the effect of acute as well as 1- or 2-weeks delayed intrathecal anti-Nogo-A antibody infusions on the regeneration of corticospinal tract (CST) axons and the recovery of motor function after large but anatomically incomplete thoracic spinal cord injuries in adult rats. We found that lesioned CST fibers regenerated over several millimeters after acute or 1-week-delayed treatments, but not when the antibody treatment was started with a delay of 2 weeks. Swimming and narrow beam crossing recovered well in rats treated acutely or with a 1-week delay with anti-Nogo-A antibodies, but not in the 2-week-delayed group. These results show that the time frame for treatment of spinal cord lesions with anti-Nogo-A antibodies is restricted to less than 2 weeks in adult rodents.

                        /forum/showthread.php?t=76585&page=6
                        Last edited by GRAMMY; 05-03-2012, 12:46 PM.
                        http://spinalcordresearchandadvocacy.wordpress.com/

                        Comment


                        • #13
                          This is not the sort of thread I expect from an SCI Nurse on carecure.

                          Comment


                          • #14
                            Originally posted by rjg View Post
                            This is not the sort of thread I expect from an SCI Nurse on carecure.
                            seriously? you no read?

                            Comment


                            • #15
                              Originally posted by Barrington314mx View Post
                              seriously? you no read?
                              I just expect a little more from the carecure elite. My mistake, I guess.

                              Comment

                              Working...
                              X